Drug development for rare neurological diseases
CHORD Therapeutics is a clinical stage biotech incorporated in Geneva, Switzerland. The company is currently in discussions with investors to provide venture capital for development of CRD1.
CHORD Therapeutics is dedicated to repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation, to bring a new effective therapy to patients with life-threatening and severely disabling neurological diseases.
Last updated: 3 January 2019